Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Toripalimab in High Risk Localized Colon Cancer With Mismatch Repair Deficiency
NCT07140679Phase 2Recruiting
- Sponsor
- Emory University
- Start
- Sep 2025
- Primary completion
- Jul 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in colon cancer, sponsored by Emory University. Primary endpoint: Disease-Free Survival at 3 years. Started Sep 2025; status: recruiting.
02
Drugs
toripalimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT07140679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07140679.